Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Receivables: 2010-2025

Historic Receivables for Arrowhead Pharmaceuticals (ARWR) over the last 8 years, with Sep 2025 value amounting to $6.8 million.

  • Arrowhead Pharmaceuticals' Receivables was N/A to $6.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $23.9 million, marking a year-over-year change of. This contributed to the annual value of $6.8 million for FY2025, which is N/A change from last year.
  • Latest data reveals that Arrowhead Pharmaceuticals reported Receivables of $6.8 million as of Q3 2025, which was down 29.64% from $9.7 million recorded in Q2 2025.
  • Over the past 5 years, Arrowhead Pharmaceuticals' Receivables peaked at $70.0 million during Q1 2023, and registered a low of $239,000 during Q2 2022.
  • For the 3-year period, Arrowhead Pharmaceuticals' Receivables averaged around $16.2 million, with its median value being $5.9 million (2024).
  • As far as peak fluctuations go, Arrowhead Pharmaceuticals' Receivables crashed by 98.55% in 2021, and later soared by 25,727.20% in 2022.
  • Quarterly analysis of 5 years shows Arrowhead Pharmaceuticals' Receivables stood at $250,000 in 2021, then soared by 25,727.20% to $64.6 million in 2022, then skyrocketed by 1,171.55% to $3.0 million in 2023, then reached $5.0 million in 2024, then reached $6.8 million in 2025.
  • Its Receivables stands at $6.8 million for Q3 2025, versus $9.7 million for Q2 2025 and $2.4 million for Q1 2025.